BetterLife Pharma annual r&d spending
2018
2019
2020
2021
2022
2023
2024
2025
2026
BetterLife Pharma R&D Spending Growth & History (BETRF)
BetterLife Pharma's r&d spending was $85,672 for fiscal 2026.
View full BetterLife Pharma company overviewBetterLife Pharma annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2026 | 2026-01-31 | $85,672 | −$338,665 | −79.81% |
| 2025 | 2025-01-31 | $424,337 | −$146,610 | −25.68% |
| 2024 | 2024-01-31 | $570,947 | −$2.1M | −78.67% |
| 2023 | 2023-01-31 | $2.7M | −$2.7M | −50.61% |
| 2022 | 2022-01-31 | $5.4M | $5.1M | +1803.98% |
| 2021 | 2021-01-31 | $284,700 | $220,933 | +346.47% |
| 2020 | 2020-01-31 | $63,767 | −$366,689 | −85.19% |
| 2019 | 2019-01-31 | $430,456 | $339,630 | +373.93% |
| 2018 | 2018-01-31 | $90,826 | — | — |
BetterLife Pharma quarterly r&d spending
Q1.19
Q1.20
Q1.26
Q2.26
Q3.26
Q4.26
Q1.27
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q1 2027 | 2026-04-30 | $21,502 | $7,879 | +57.84% |
| Q4 2026 | 2026-01-31 | $58,495 | — | — |
| Q3 2026 | 2025-10-31 | $11,976 | — | — |
| Q2 2026 | 2025-07-31 | $1,578 | — | — |
| Q1 2026 | 2025-04-30 | $13,623 | — | — |
| Q1 2020 | 2019-04-30 | $59,487 | −$49,314 | −45.32% |
| Q1 2019 | 2018-04-30 | $108,801 | — | — |
BetterLife Pharma r&d spending trends
Over the last five fiscal years, BetterLife Pharma's r&d spending decreased from $284,700 to $85,672, a change of −$199,028. The latest reported quarter, Q1 2027, shows $21,502.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review BetterLife Pharma source filings ↗